Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Working backwards: AWS’s strategy for pharma’s cloud-enabled transformation

By Brian Buntz | June 25, 2023

Cloud computing illustrated

[Bo Dean/Adobe Stock]

The meteoric rise of the AI sector is hard to fathom. Projections from Precedence Research suggest that the global AI market could balloon by 2600% from 2022 to 2032, hitting $1.87 trillion — an annual growth rate of 39%.

In pharma, AI and data science demand is surging though overall growth is sluggish. Despite advances such as the rapid development of COVID-19 vaccines, the broader sector has struggled to keep up with the overall stock market. But the future could tell a different story. McKinsey projects that the pharma and medical products sector could gain 9% in EBITDA from cloud computing.

To tap this potential, cloud vendors are allying with pharma companies. “Nine of the top 10 pharma companies in the world have a large majority of the workloads running on AWS,” noted Tehsin Syed, general manager of AWS Health. These workloads encompass diverse areas including IT infrastructure, business operations and drug discovery. “There is quite a bit of adoption of cloud technologies within pharma companies that we’re seeing,” Syed said.

AWS has the biggest market share in the overall cloud market. Notable pharma customers include Bristol-Myers Squibb, Gilead, Novartis and Moderna. Extending its partnerships in the sector, AWS joined AstraZeneca, Merck KGaA, Pfizer and Teva and Israel Biotech Fund in 2021 to establish the AION Labs innovation center dedicated to AI technologies and computational science in drug discovery and development.

The second biggest cloud player is Microsoft Azure, whose pharma clients include Bayer, Sanofi, Biogen and Johnson & Johnson.

Working backwards: A defining AWS principle

Tehsin Syed

Tehsin Syed

A cornerstone of AWS’s approach is the “working backwards” philosophy, propagated by Amazon founder Jeff Bezos. This philosophy places the customer at the starting point, from which point AWS works backwards to fulfill their needs. According to Syed, this approach has been crucial in AWS’s pharma partnerships.

“In AWS, you know, our core approach is really to understand what are customer pain points,” Syed said. “What’s the outcome and value that they’re trying to achieve? And then how can we really, you know, remove those pain points and deliver that value with our technology.”

AWS’s focus is twofold: comprehending its customers’ challenges and goals while anticipating future technical advances to proactively meet customer’s needs. “This proactive approach means we’re always ready to provide the most cutting-edge capabilities,” Syed said.

Moderna and AWS: A pharma cloud case study

“If you consider the unexpected nature of events like the COVID-19 pandemic, it’s clear that this was something no one could have predicted,” Syed said. Take Moderna, an existing AWS partner, as an example. Thrust into the battle against COVID-19, Moderna was able to tap into its already established AWS cloud resources, including machine learning capabilities and computational power. “This enabled Moderna to model the virus in just two days and develop a vaccine that interacted with it incredibly quickly,” Syed said.

In 2020, Moderna’s CEO, Stéphane Bancel, underscored the role of the cloud during this period. “So once you figure out how to make it work once … then you can have a lot of new products come in very quickly and the return on investments is very spectacular because you don’t have to reinvent everything. You just fly,” he told CNBC.

Barbara Salami, vice president, digital for commercial at Moderna, touched on this approach AWS re:Invent 2022. She said, “Moderna aims to ‘push past possible.'” Salami added that the team, including its CEO, champions audacious ideas. “And we really start there and then we start to work backwards — because we believe that even if we don’t get to the moon, and we only hit 20% of our target, we will still be a billion times better” than if they hadn’t dared to aim so high.

Exploring the potential of cloud and AI in shaping pharma’s future

Line graph showing an increasing trend in the number of mentions of 'Artificial Intelligence' in the PubMed database publications from 1988 to 2022.

Trend of ‘Artificial Intelligence’ Mentions in PubMed Publications (1988-2022)

Ultimately, McKinsey predicts life science companies could gain $40 billion in EBITDA by 2030 using the cloud, improving IT, data and standardization to curb cost overruns.

“Pharma companies are turning quite a bit to the cloud to say, ‘Okay, this is really difficult to keep up with on premises. It’s bursty,’” Syed said. “And we really want the ability to have access to that compute to those GPUs to kind of that manage infrastructure.'”

AWS’s broader goal is to pinpoint high-impact areas where they can assist their customers, thereby removing the ‘undifferentiated heavy lifting.’ This strategy empowers customers to concentrate on their areas of expertise, with AWS handling the complex technological aspects. AWS’s approach embodies its commitment to promoting innovation and enabling customers to excel in their fields.

Despite currently holding the largest market share in the cloud market, AWS continues to focus on potential technological advances and building capabilities to meet future needs. Syed refers to this as “looking around corners on behalf of customers.”


Filed Under: Data science, Industry 4.0, machine learning and AI
Tagged With: artificial intelligence, AWS, AWS Cloud, cloud computing, data science, digital transformation, pharmaceutical industry, pharmaceutical research and development
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE